ResultsIQ

ResultsIQ › Latest results › Zydus Lifesciences Limited

Zydus Lifesciences Limited Q3 FY26 results press release summary

NSE: ZYDUSLIFE · BSE: 532321

Results press release of 9 Feb 2026, summarised by AI from the filing.

Preparing to file NDA of Saroglitazar Magnesium with USFDA during the current quarter.

Key takeaways

  1. NDA filing Preparing to file NDA of Saroglitazar Magnesium with USFDA during the current quarter.
  2. Consumer wellness Revenue ₹9,578 mn, up 113% y-o-y, with full quarter of CCL consolidation.
  3. India formulations Branded business grew 14% y-o-y, faster than the market, driven by innovation products and pillar brands.
  4. Exceptional expense One-time impact of increase in gratuity and leave encashment liability pursuant to new labour code.

Original filing on BSE

Zydus Lifesciences Limited Q1 FY27 results

As filed: Revenue ₹8,017 cr (+22% year on year), EBITDA ₹1,929 cr (−8% year on year), PAT ₹990 cr (−35% year on year), EBITDA margin 24.1% (−771 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹7,587 cr (+16% year on year), EBITDA ₹2,554 cr (+20% year on year), PAT ₹1,341 cr (+9% year on year), EBITDA margin 33.7% (+110 bps). Score 37 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit before exceptional items growth was well below it. EBITDA margin rose 110 bps year on year. Consolidated profit +8% but standalone -39%. Revenue rose ₹1,059 cr on a year ago, more than the ₹994 cr it added the year before. Share price after the results: +8.4% in 30 days (Nifty 500: +3.3%).
  • Q3 FY26: Revenue ₹6,865 cr (+30% year on year), EBITDA ₹1,816 cr (+31% year on year), PAT ₹1,023 cr (0% year on year), EBITDA margin 26.5% (+14 bps). Score 63 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was below it. EBITDA margin rose 14 bps year on year. Profit fell 17% from last quarter. Share price after the results: +3.8% in 30 days (Nifty 500: −5.9%).
  • Q2 FY26: Revenue ₹6,123 cr (+17% year on year), EBITDA ₹2,015 cr (+38% year on year), PAT ₹1,239 cr (+35% year on year), EBITDA margin 32.9% (+499 bps). Score 76 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA growth was well above it; profit growth was in line with it. EBITDA margin rose 499 bps year on year. Revenue fell 7% from last quarter. Profit rose ₹319 cr on a year ago, more than the ₹117 cr it added the year before. Share price after the results: −4.1% in 29 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹6,574 cr (+6% year on year), EBITDA ₹2,089 cr (0% year on year), PAT ₹1,521 cr (+3% year on year), EBITDA margin 31.8% (−179 bps). Score 15 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin fell 179 bps year on year. Consolidated profit +3% but standalone -77%. Revenue rose ₹366 cr on a year ago, against ₹1,068 cr the year before. Share price after the results: +9.2% in 30 days (Nifty 500: +2.1%).
  • Q4 FY25: Revenue ₹6,528 cr (+18% year on year), EBITDA ₹2,126 cr (+30% year on year), PAT ₹1,244 cr (+22% year on year), EBITDA margin 32.6% (+310 bps). Score 62 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit before exceptional items growth was below it. EBITDA margin rose 310 bps year on year. Consolidated profit 0% but standalone +100%. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue rose ₹994 cr on a year ago, more than the ₹523 cr it added the year before. Share price after the results: +4.3% in 30 days (Nifty 500: −0.4%).
  • Q3 FY25: Revenue ₹5,269 cr (+17% year on year), EBITDA ₹1,387 cr (+26% year on year), PAT ₹1,026 cr (+30% year on year), EBITDA margin 26.3% (+184 bps). Score 65 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 184 bps year on year. Profit rose ₹236 cr on a year ago, more than the ₹159 cr it added the year before.
  • Q2 FY25: Revenue ₹5,237 cr (+20% year on year), EBITDA ₹1,462 cr (+28% year on year), PAT ₹920 cr (+15% year on year), EBITDA margin 27.9% (+169 bps). Score 68 of 100, Above trend. EBITDA margin rose 169 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 16% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Zydus Lifesciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.